Bohigas consolidates sales of mid-range and high-end products
Specifically, Bohigas has sold 3% more Reserva and Gran Reserva cavas than the previous year and 39% more than three years ago (2014)
In 2017, Caves Bohigas consolidated sales of medium and high-end products, which already represent 49% of the total. Specifically, Bohigas has sold 3% more Reserva and Gran Reserva cavas than the previous year and 39% more than three years ago (2014), when sales increased in the United States and Spain.
By country, Belgium continues to be the main buyer of Bohigas, with 28% of the market share (in 2016 it was 35%), followed by the United States, which has risen slightly, from 22% -in 2016- to 23% , and Spain, where sales are maintained compared to the previous year and represent 19% of the total.
At the same time, the growth of the business in the Netherlands, Poland and, above all, South Korea, where sales have increased by 70% compared to the previous year, stands out. However, Korea only accounts for 5% of the winery's total wine and cava sales, behind other countries such as Germany or Great Britain, with 9% and 6%, respectively.
Regarding turnover, Bohigas maintains the global figures for 2015 and 2016 and, regarding production, in 2017, the winery produced 550,000 bottles, of which 500,000 were cava and 50,000 were wine. .
In recent years, Bohigas has focused its efforts on the commercial department of the company, with new actions that aim to make the Bohigas brand better known nationally and internationally and with the aim of opening new markets in the US and Asia.
Bohigas is also committed to innovation, restructuring the range of wines towards autochthonous varieties -with products such as "Inicis", the new Bohigas Sumoll from the family range- and with a new design of the presentations. Likewise, the winery works to improve the offer of wine tourism activities and services for individuals and companies, adapting them to the growing demand of tourism in the area and establishing collaboration agreements with local agents.